Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibikase Therapeutics (IKT) Change in Receivables (2021 - 2023)

Historic Change in Receivables for Inhibikase Therapeutics (IKT) over the last 3 years, with Q3 2023 value amounting to -$79602.0.

  • Inhibikase Therapeutics' Change in Receivables fell 119193.42% to -$79602.0 in Q3 2023 from the same period last year, while for Jun 2024 it was -$79602.0, marking a year-over-year decrease of 20896.62%. This contributed to the annual value of -$39881.0 for FY2023, which is 4323.64% up from last year.
  • Per Inhibikase Therapeutics' latest filing, its Change in Receivables stood at -$79602.0 for Q3 2023, which was down 119193.42% from $15083.0 recorded in Q2 2023.
  • Inhibikase Therapeutics' 5-year Change in Receivables high stood at $332774.0 for Q1 2021, and its period low was -$369099.0 during Q3 2021.
  • Over the past 3 years, Inhibikase Therapeutics' median Change in Receivables value was $7290.0 (recorded in 2022), while the average stood at $0.18.
  • Data for Inhibikase Therapeutics' Change in Receivables shows a peak YoY increase of 13963.32% (in 2023) and a maximum YoY decrease of 119193.42% (in 2023) over the last 5 years.
  • Over the past 3 years, Inhibikase Therapeutics' Change in Receivables (Quarter) stood at -$107341.0 in 2021, then soared by 124.26% to $26041.0 in 2022, then plummeted by 405.68% to -$79602.0 in 2023.
  • Its last three reported values are -$79602.0 in Q3 2023, $15083.0 for Q2 2023, and $24638.0 during Q1 2023.